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Background: Perhaps reflecting that children with COVID-19 rarely exhibit severe respiratory symptoms and
often remain asymptomatic, little attention has been paid to explore the immune response in pediatric
COVID-19. Here, we analyzed the phenotype and function of circulating neutrophils from children with
COVID-19.
Methods: An observational study including 182 children with COVID-19, 21 children with multisystem
inflammatory syndrome (MIS-C), and 40 healthy children was performed in Buenos Aires, Argentina. Neutro-
phil phenotype was analyzed by flow cytometry in blood samples. Cytokine production, plasma levels of IgG
antibodies directed to the spike protein of SARS-CoV-2 and citrullinated histone H3 were measured by ELISA.
Cell-free DNA was quantified by fluorometry.
Findings: Compared with healthy controls, neutrophils from children with COVID-19 showed a lower expres-
sion of CD11b, CD66b, and L-selectin but a higher expression of the activation markers HLA-DR, CD64 and
PECAM-1 and the inhibitory receptors LAIR-1 and PD-L1. No differences in the production of cytokines and
NETs were observed. Interestingly, the expression of CD64 in neutrophils and the serum concentration of IgG
antibodies directed to the spike protein of SARS-CoV-2 distinguished asymptomatic from mild and moderate
COVID-19.
Interpretation: Acute lung injury is a prominent feature of severe COVID-19 in adults. A low expression of
adhesion molecules together with a high expression of inhibitory receptors in neutrophils from children
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Among the most intriguing observations in Coronavirus disease
2019 (COVID-19) is the reduced incidence and mortality in children
[1]. Clinical manifestations usually include fever, cough, nasal con-
gestion, sore throat and fatigue, and up to one-third of the infected
children remains asymptomatic [2]. Epidemiological data from
Argentina as of December 9, 2020, show that only 0.3% of infected
children were admitted to Pediatric Intensive Care Unit (PICU) and
less than 0.1% required mechanical ventilation (https://www.argen
tina.gob.ar/salud/coronavirus-COVID-19/sala-situacion). The view
that acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infec-
tion in children is always associated to a mild disease has been chal-
lenged by the emergence of a novel multisystem inflammatory
syndrome in children (MIS-C) associated to a previous infection by
SARS-CoV-2 [3].
The reasons underlying the mild and often asymptomatic course
of COVID-19 in children are unclear. A decreased expression of host
factors required for the progression of viral infection in the airway
epithelium such as the viral entry receptor angiotensin-converting
enzyme 2 and the transmembrane serine protease 2 might explain,
at least in part, the mild clinical course of pediatric infection [46].
On the other hand, differences in the immune response between chil-
dren and adults might also be involved [79]. In recent months, sev-
eral works directed to analyze the immune response in MIS-C havebeen published. However, not enough attention has been paid to
study the immune response in children during the acute phase of
COVID-19. The observations made in this field are very scarce and do
not allow to establish a causal relationship between the immune
response and the course of infection.
Here, we focus on the phenotype and function of neutrophils in
pediatric COVID-19. We found that neutrophils from infected chil-
dren express a particular signature characterized by a reduced
expression of adhesion molecules involved in neutrophil migration
together with an increased expression of both, the inflammatory
markers CD64, HLA-DR and PECAM-1 and the inhibitory receptors
leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1) and
programmed death-ligand 1 (PD-L1). Moreover, we found that symp-
tomatic and asymptomatic children with COVID-19 can be differenti-
ated based on the neutrophil expression of CD64 and the plasma
levels of IgG antibodies against the spike protein of SARS-CoV-2.2. Methods
2.1. Study population
This observational study was conducted in Buenos Aires City and
Buenos Aires province, Argentina, between May and October 2020.
We recruited girls, boys and adolescents aged between 5 months and
15 years admitted to the Hospital General de Ni~nos Pedro de Elizalde,
Hospital Nacional Prof. Alejandro Posadas, Hospital Municipal Diego
Thompson, Clínica del Ni~no de Quilmes, Hospital Naval Cirujano
Mayor Dr. Pedro Mallo and Hospital General de Agudos Dr. J. A
Fernandez. Patients were divided into two main cohorts: 1- patients
with active SARS-CoV-2 infection confirmed by PCR of nasopharyn-
geal swabs (COVID-19, n = 174) and, 2- MIS-C patients with previous
SARS-CoV-2 infection confirmed by PCR of nasopharyngeal swabs
and/or SARS-CoV-2 IgG antibody-positive serology (n = 21). Disease
severity was classified into four clinical types (asymptomatic, mild,
moderate and severe), according to the Health Ministry from Argen-
tina and the WHO interim guidance. Asymptomatic patients (n = 29)
remain asymptomatic throughout the course of the infection. They
were admitted after SARS-CoV-2 infection was confirmed by PCR.
Mild patients (n = 102) do not present evidence of viral pneumonia
or hypoxia. Symptoms are non-specific and could include fever,
fatigue, headache, myalgia, cough, abdominal pain and diarrhea.
Moderate patients (n = 43) present symptoms and signs of non-
severe pneumonia (cough or fast breathing and/or chest indrawing),
and include patients with comorbidities such as cardiac or respiratory
disease, immunodeficiency and prematurity. Our cohort did not con-
tain children under severe disease. Characteristics of children with
COVID-19 are shown in Table 1 and Table S1. MIS-C was diagnosed
according to WHO criteria: -fever during more than 3 days; -two of
the following signs (rash or bilateral non-purulent conjunctivitis,
mucocutaneous inflammation signs, hypotension, shock, myocardial
dysfunction, pericarditis, valvulitis, coronary abnormalities, coagul-
opathy, and/or acute gastrointestinal symptoms); -elevated markers
of inflammation, -no other microbial cause; and -evidence of previ-
ous SARS-CoV-2 infection (PCR or serology positive). Clinical features
of MIS-C are shown in Table 1 and Table S2. Eight children who had
recovered from COVID-19 disease (4 to 5 weeks post illness-onset)
were also included. Data are shown in Table S3. Our control cohort
included forty children age and sex matched that were admitted to
Table 1
Characteristics of children with COVID-19, MIS-C and healthy controls
Characteristics Control (n=40) COVID-19 (n=174) MIS-C (n=21) P
Age, years 5 (1-9) 4 (0.5-10) 6 (3-11)
<1, n (%) 9 (23) 46 (26) 2 (10)
1-5, n (%) 17 (42) 52 (30) 8 (38)
6-10, n (%) 8 (20) 33 (19) 6 (29)
>10, n (%) 6 (15) 43 (25) 5 (24)
Female, n (%) 24 (60) 80 (46) 5 (24) *Control vs MIS-C
SARS-CoV-2 PCR positive, n (%) 0 174 (100) 10 (48)
SARS-CoV-2 IgG antibody positive, n (%) 0 53 (31) 19 (90)
SARS-CoV-2 IgM antibody positive, n (%) 0 68 (39) 10 (48)
Close contact positive, n (%) 0 117 (67) 13 (62)
Laboratory





Neutrophils, % N/A 45 (31-67) 78 (66-90) ****COVID-19 vs MIS-C
Lymphocytes, % N/A 38 (20-54) 23 (11-34) **COVID-19 vs MIS-C
Neutrophil-to-lymphocyte ratio N/A 1 (0.6-4) 4 (2-9) **COVID-19 vs MIS-C
Coinfections, n (%)
None 40 (100) 166 (95) 21 (100)
Bacterial 0 8 (5) 0
Viral 0 0 0
Comorbidities, n (%)
None 37 (92) 136 (78) 16 (76)
Heart disease 0 1 (1) 0
Renal disease 0 2 (1) 0
Lung disease 0 20 (12) 4 (19)
Prematurity 0 3 (2) 0
Autoimmunity 0 3 (2) 0
Cancer 0 4 (2) 0
Obesity 2 (5) 4 (2) 1 (5)
Diabetes 1 (3) 1 (1) 0
Signs and symptoms, n (%)
Fever N/A 81 (47) 20 (95) ****COVID-19 vs MIS-C
Cough N/A 34 (20) 2 (10)
Dyspnea N/A 16 (9) 1 (5)
Odynophagia N/A 24 (14) 4 (19)
Myalgia N/A 9 (5) 2 (10)
Pneumonia N/A 12 (7) 3 (14)
Gastrointestinal N/A 23 (13) 12 (57) ****COVID-19 vs MIS-C
Haematological N/A 0 12 (57) ****COVID-19 vs MIS-C
Mucocutaneous N/A 0 8 (38) ****COVID-19 vs MIS-C
Cardiac abnormalities N/A 0 12 (57) ****COVID-19 vs MIS-C
Neurological N/A 0 1 (5)
Shock N/A 0 5 (24) ****COVID-19 vs MIS-C
PICU admission, n (%) 0 2 (1) 12 (57) ****COVID-19 vs MIS-C
Medications, n (%)
None 40 (100) 148 (85) 0
Corticosteroid 0 18 (10) 20 (95) ****COVID-19 vs MIS-C
IVIG 0 0 20 (95) ****COVID-19 vs MIS-C
Antibiotic 0 8 (5) 2 (10)
Enoxaparin 0 0 14 (67) ****COVID-19 vs MIS-C
Aspirin 0 0 15 (71) ****COVID-19 vs MIS-C
Inotropic 0 0 9 (43) ****COVID-19 vs MIS-C
Respiratory status, n (%)
Mechanical ventilation 0 0 5 (24) ****COVID-19 vs MIS-C
Oxygen requirement 0 28 (16) 1 (5)
Room air 40 (100) 146 (84) 16 (76)
Data are expressed as median values (25th75th percentile) unless otherwise indicated. Abbreviations: IVIG, Intravenous Immuno-
globulin; PICU, pediatric intensive care unit; WBCs, white blood cells. Mann-Whitney and Kruskall-Wallis tests were used for cuantita-
tive variables. Fishers exact test and Chi-square test were adopted for category variables. Only statistical differences are shown.
*p<0.05, **p<0.01, ****p<0.0001.
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They had no history of recent respiratory infection or close-con-
tact and they were negative for IgM and IgG antibodies directed
to SARS-CoV-2.
2.2. Study approval
This study was conducted in accordance with the Declaration of
Helsinki. The Institutional Review Board at institutions participants
reviewed and approved the sample collection and the overall study(Hospital General de Ni~nos Pedro de Elizalde protocol reference
1226/20, and Hospital General de Agudos Dr. J. A Fernandez protocol
reference 1720/20).
2.3. Ethics statement
Parents or legal guardians from children under 8 years provided
written, informed consent. Children older than 8 years old provided
written, informed assent and their parents or legal guardians also
provided written, informed consent.
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0.51 mL of whole blood samples were obtained within 72 h of
hospital admission. After being centrifuged for 10 min at 1000 rpm,
plasma was separated and stored at 80 °C until used. Whole blood
samples were used for flow cytometry and/or cell isolation.
2.5. Neutrophil isolation
Neutrophils were isolated within the first 3 h of blood collection
by Ficoll-Hypaque Plus (GE Healthcare, 17144003) gradient centrifu-
gation and dextran sedimentation (Sigma Aldrich, 31392), as
described [10]. Cell suspensions containing >96% neutrophils were
suspended in RPMI 1640 medium (Sigma-Aldrich, R8758) with 10%
FCS (Natocor; complete medium).
2.6. Immunophenotyping by flow cytometry
Whole blood (100 mL) was stained with the antibody cocktail mix
for 20 min at room temperature. After being washed with PBS 0.1%
BSA, erythrocytes were lysed and cells were fixed using Lysing buffer
(BD Biosciences, 555899). The following conjugated-monoclonal anti-
bodies were used: anti-CD14 (BV421, 367144), anti-CD15 (PerCP,
301922), anti-CD11b (PE-Cy7, 301322), anti-CD66b (FITC, 305104),
anti-CD62L (L-selectin, PE, 304806), anti-HLA-DR (APC, 307610),
anti-PECAM-1 (Pacific Blue, 303114), anti-LAIR-1 (Alexa Fluor 647,
342802), anti-PD-L1 (BV510, 329734), anti-CD16 (APC, 980104), anti-
CD32 (PE-Cy7, 303214) and anti-CD64 (FITC, 305006) all from Biole-
gend. Control samples were incubated with an isotype-matched anti-
body. Statistical analyses were based on at least 100,000 events gated
on the population of interest. Data were acquired using a FACSCanto
II (Becton Dickinson) and analyzed with FlowJov10.6.2.
2.7. Neutrophil cultures
To test the spontaneous cytokine secretion, neutrophils (5 £ 106/
mL) were suspended in complete medium and cultured in U-bottom
96-well plates (Greiner-Bio One, 650161) for 18 h at 37 °C. To test the
response to TLR 7/8 agonist, neutrophils were stimulated with 5 mM
of resiquimod (R848, Sigma-Aldrich, SML0196). To test neutrophil
extracellular traps (NETs) release, neutrophils (1 £ 106/mL) were sus-
pended in FCS-free culture medium and cultured in 48-well plates
(Greiner-Bio One, 677180) for 4 h at 37 °C. Then, cells were treated
with a low concentration of DNase I (2 U/mL; Promega, M6101) for
15 min at 37 °C to detach NET that remained attached to the neutro-
phil surface [11]. After the addition of EDTA (5 mM) to prevent fur-
ther DNase activity [12], the samples were centrifuged and the
supernatants were collected and store at 80 °C until use.
2.8. Analysis of cytokine production
Levels of IL-1b (437015), IL-6 (430501) and IL-8 (431501, Biole-
gend) in plasma and neutrophil supernatants were analyzed by ELISA
according to the manufacturer's instructions.
2.9. Cell-free DNA quantitation
Cell-free DNA was quantified in plasma and/or in the supernatants
of neutrophil cultures using the Quant-iT PicoGreen dsDNA Assay Kit
(Molecular Probes, P11496) according to the manufacturer's instruc-
tions. Briefly, samples were diluted 1:10 or 1:5, for plasma and super-
natants respectively, in 10 mM Tris-HCl 1 mM EDTA buffer, and
Quant-iT PicoGreen dsDNA reagent was added in a 1:1 ratio. After
incubation for 3 min at room temperature in the dark, the fluores-
cence was read in a SpectraMax i3x Multi-Mode Plate Reader(Molecular Devices; ex. 480 nm, em. 520 nm). A standard curve was
plotted and a regression analysis was applied.
2.10. Quantification of citrullinated histone H3
Citrullinated histone H3 was quantified in plasma using the Citrul-
linated Histone H3 (Clone 11D3) ELISA Kit (Cayman, 501620) accord-
ing to the manufacturer's instructions.
2.11. Analysis of plasma SARS-CoV-2specific IgG antibodies
Plasma levels of IgG antibodies directed to the spike protein of SARS-
CoV-2 were analyzed by ELISA (COVIDAR IgG), as described [13]. Briefly,
samples were diluted 1:10 in PBS-T containing 0.8% casein and incu-
bated for 1 h at 37 °C. After washing with PBS-T, HRP-conjugated goat
mouse anti-human IgG antibodies was added and incubated for 30 min
at 37 °C, followed by TMB Substrate Reagent. The absorbance (OD) was
measured at 450 nm. The cut-off was calculated as the mean OD of the
negative sera plus 0.2. Samples with OD lower than the cut-off were
considered negative for anti-SARS-CoV-2 IgG antibodies.
2.12. Statistics
Clinical characteristics were summarized using descriptive statis-
tics. Categorical variables are reported as numbers and percentages.
Quantitative variables are reported as medians and interquartile
ranges and presented as medians and min to max in the figures. Out-
liers in experimental data were detected by the application of ROUT
method and then excluded from the analysis. The normality of exper-
imental data was evaluated by the Shapiro-Wilk test. Two groups
were compared using the Wilcoxon signed-rank test, Mann-Whitney
U test or Fisher`s exact test. Three or more groups were compared
using the Kruskall-Wallis test followed by Dunn's multiple compari-
son test or Chi-square test followed by Bonferroni test (the exact
method used is stated in the figure legends). Significance between 2
continuous variables was calculated by using a Spearman correlation
test. The sample size was not calculated by statistical methods, but
was determined based on our previous experience. Statistical signifi-
cances are indicated in the figures by asterisks as follows *p < 0.05,
**p < 0.01, ***p < 0.001 or ****p < 0.0001. Analysis and visualizations
were performed using GraphPad Prism.v.8 (GraphPad Software, CA,
USA) and SPSS software v.19.0 (SPSS Corp., Armonk, NY, USA).
2.13. Role of the funding source
The funders had no role in study design, data collection, analysis
and interpretation, writing and submission of the manuscript.
3. Results
3.1. Study cohorts
We recruited a total of 203 girls, boys and adolescents admitted to
different hospitals from Buenos Aires city and surroundings with clinical
manifestations of SARS-CoV-2 infection between May and October
2020. Samples from children with COVID-19 and MIS-C were obtained
within 2472 h of being admitted, after the initiation of therapeutic
interventions including steroids. Children with COVID-19 (n = 174)
included asymptomatic (n = 29), mild (n = 102) and moderate (n = 43)
patients. The median age (25th75th percentile) of COVID-19 group
was 4 years (0.510 years), of whom 45% (n = 79) were girls. Only 1%
(n = 2) of children with COVID-19 were admitted to PICU. Table 1 and
Table S1 summarize the characteristics of children with COVID-19
included in the study. Regarding the MIS-C group (n = 21), the median
(25th75th percentile) age was 6 years (310 years), of whom 24%
(n = 5) were girls. More than half of MIS-C patients required intensive
V. Seery et al. / EBioMedicine 67 (2021) 103357 5care, 95% (n = 20) needed steroids and gammaglobulin, 43% (n = 9)
needed inotrope treatment and 24% (n = 5) requiredmechanical ventila-
tion. Data fromMIS-C are shown in Tables 1 and Table S2. Samples from
eight children recovered from COVID-19 were obtained within 4 to 5
weeks after the onset of disease. Six of them had mild symptoms and 2
moderate diseases at diagnosis. The median age (25th75th percentile)
of recovered COVID-19 group was 4 years (0.612 years), of whom 38%
(n = 3) were girls. All recovered children tested positive for SARS-CoV-2
in nasopharyngeal swabs by PCR at hospital admission and 88% (n = 7)
were positive for IgG antibodies directed to SARS-CoV-2. Data of this
cohort is shown in Table S3. No fatal outcome was observed in any
cohort.
3.2. Neutrophils from children with symptomatic COVID-19 express an
atypical phenotype
We characterized the phenotype of neutrophils from children
with COVID-19 by flow cytometry in whole blood samples. The gat-
ing strategy used is shown in Fig. S1. Neutrophil activation is charac-
terized by an increased expression of CD11b and CD66b and a down
regulation of L-selectin expression [14,15]. The analysis of neutrophil
phenotype in children with COVID-19 revealed a particular signature.
In comparison with healthy controls, neutrophils from children with
COVID-19 showed a reduced expression of CD11b, CD66b, and L-
selectin and an enhanced expression of two inflammatory markers
[1618], HLA-DR and PECAM-1 (Fig. 1ac). A positive correlation
was found between the expression of CD11b and CD66b in neutro-
phils from children with COVID-19 (Fig. 1d).Fig. 1. Low expression of CD11b, CD66b, and L-selectin and high expression of HLA-DR and
CD62L, HLA-DR and PECAM-1 positive cells in neutrophils from healthy (n = 22) and COVID-
CD11b and CD66b MFI analyzed in the cohorts described in (a). (c) Representative histogram
Correlation between CD66b and CD11b expression (MFI) in neutrophils from children with
were determined by Kruskal-Wallis test with Dunn's posttest, Mann-Whitney U test and S
circles), COVID-19 (blue circles) (For interpretation of the references to color in this figure legNeutrophil activation is usually associated with an augmented
expression of inhibitory receptors that limits its inflammatory poten-
tial by increasing the neutrophil activation threshold [19]. As shown
in Fig. 2a,b, the expression of the inhibitory receptors LAIR-1 and PD-
L1 was significantly higher in COVID-19 neutrophils compared with
controls. Moreover, considering the important role that the receptors
for the Fc portion of IgG (FcgRs) play in both, the protection against
viral infections and the immunopathogenesis associated to viral
infections in the airway [20], we also analyzed the expression of
FcgRIII (CD16), FcgRII (CD32), and FcgRI (CD64). Neutrophils from
children with COVID-19 showed a slight but significant reduction in
the expression of CD16 compared with healthy neutrophils, while no
changes in the expression of CD32 was observed. Interestingly,
whereas no expression of CD64 was found in neutrophils from
healthy controls, neutrophils from children with COVID-19 showed a
wide range of CD64 expression ranged from 0 to 100% (Fig. 2c-d). We
conclude that neutrophils from children with COVID-19 express a
distinct inflammatory phenotype characterized by the down-regula-
tion of cell-surface molecules involved in cell migration and an
increased expression of both, inflammatory markers (HLA-DR,
PECAM-1 and CD64) and inhibitory molecules (LAIR-1 and PD-L1).
3.3. Neutrophils from children with COVID-19 and healthy donors show
a similar pattern of cytokine production and NETs release
Previous studies have shown that moderate and severe COVID-19
in adults is associated with increased plasma levels of inflammatory
cytokines and NETs [2123]. As shown in Fig. 3a, the plasmaPECAM-1 in neutrophils from children with COVID-19. (a) Frequency of CD11b, CD66b,
19 children (n = 65 for CD11b, n = 22 for PECAM-1 and n = 35 for all other markers). (b)
s of CD11b and CD66b expression. Gray filled histograms show the isotype controls. (d)
COVID-19 (n = 32). Median and min to max of n donors are shown in a and b. P values
pearman correlation test: ** p < 0.01, *** p < 0.001, ****, p < 0.0001. Controls (white
end, the reader is referred to the web version of this article.).
Fig. 2. High expression of LAIR-1, PD-L1 and CD64 in neutrophils from children with
COVID-19. (a) Frequency of LAIR-1 and PD-L1 positive cells in neutrophils from healthy
(n = 20) and COVID-19 (n = 21). (b) Representative dot plots of LAIR-1 and PD-L1
expression in a donor from each cohort are shown. Numbers indicate the percentage
of neutrophils positive for the expression of LAIR-1 or PD-L1. (c) Frequency of positive
cells for CD16, CD32 and CD64 expression in neutrophils from healthy (n = 22) and
COVID-19 (n = 56). (d) Representative dot plots of CD16 and CD64 expression are
shown. Data show the percentages of positive cells in gated neutrophils. Median and
min to max of n donors are shown in a and c. P values were determined by Kruskal-
Wallis test with Dunn's posttest and Mann-Whitney U test: * p <0.05, ** p <0.01. Con-
trols (white circle), COVID-19 (blue circle) (For interpretation of the references to color
in this figure legend, the reader is referred to the web version of this article.).
6 V. Seery et al. / EBioMedicine 67 (2021) 103357concentrations of IL-1b, IL-6 and IL-8 were below the detection limit
of the assay in most of children with COVID-19. In addition, plasma
concentrations of both, cell-free DNA and citrullinated histone H3
were similar in COVID-19 and healthy children (Fig. 3b). We then
analyzed whether the changes in the phenotype of COVID-19 neutro-
phils were associated to a higher ability to produce inflammatory
cytokines. Purified neutrophils were cultured for 18 h and the spon-
taneous production of cytokines was analyzed. Moreover, consider-
ing that TLR7 and 8 appear to be involved in the recognition of
SARSCoV2 genome as well as in the inflammatory responses trig-
gered by SARS-CoV-2 infection [24], we also examined the produc-
tion of cytokines by neutrophils upon stimulation with the TLR7/8
agonist R848. Neutrophils from healthy donors and children with
COVID-19 produced similar levels of cytokines both spontaneously
and after being activated by the compound R848 (Fig. 3c-d). Compa-
rable levels of cell-free DNA were also observed in neutrophil super-
natants after 18 h of culture (Fig. 3e).
3.4. Expression of neutrophil adhesion molecules, inhibitory receptors
and production of inflammatory mediators does not distinguish
asymptomatic from symptomatic COVID-19 in children
We analyzed whether there was any association between the
changes in neutrophil phenotype or function and disease severity in
children with COVID-19. A cohort of MIS-C was also included in the
analysis. As shown in Fig. 4ad, the expression of CD11b, CD66b,
LAIR-1, and PD-L1 in neutrophils did not distinguish betweenasymptomatic and symptomatic children with COVID-19. However,
all these markers showed a greater expression in neutrophils from
MIS-C. Considering that neutrophil expression of CD11b and CD66b
among children with COVID-19 shows a wide distribution of values
(see Fig. 1a and b), we analyzed whether this heterogeneity could be
related to differences in the age or sex of patients. No differences
were found when data were stratified according to age, while a
higher expression of CD66b was observed in boys compared with
girls (Fig. S2ad).
We then studied whether there was any link between the levels of
IL-1b and IL-8 cytokines produced by neutrophils and disease sever-
ity. No significant differences were observed (Fig. 4e). Similarly, the
levels of cell-free DNA in both, neutrophil supernatants and plasma,
as well as the levels of citrullinated histone H3 in plasma could not
distinguish disease severity in children with COVID-19. However,
these parameters were shown to be significantly higher in MIS-C
(Fig. 4f-g).
3.5. Neutrophil expression of CD64 and plasma levels of IgG antibodies
directed to the spike protein of SARS-CoV-2 distinguish asymptomatic
from symptomatic COVID-19 in children
Interestingly, we found that the expression of CD64 clearly distin-
guished asymptomatic frommild and moderate COVID-19. Moreover,
the analysis performed in a small cohort of children recently recov-
ered from COVID-19, revealed that the expression of CD64 returned
to baseline after recovery (Fig. 5a). No differences in CD64 expression
were observed according to the age and sex within the COVID-19 and
MIS-C cohorts. (Fig. S3ab).
Severe disease in adult COVID-19 is clearly associated with the
presence of high levels of plasma anti-SARS-CoV-2 IgG antibodies
[25]. We then examined whether an enhanced antibody response
was also linked to disease progression in pediatric COVID-19. The
presence of IgG antibodies in plasma was analyzed using an ELISA
that detects IgG antibodies directed to the spike protein of SARS-
CoV-2 [13]. As shown in Fig. 5b, children with COVID-19 showed a
marked diversity in the antibody response against SARS-CoV-2, while
MIS-C showed a more robust response, perhaps reflecting the time
elapsed since the onset of SARS-CoV-2 infection. In fact, more than
90% of MIS-C had laboratory evidence of previous SARS-CoV-2 expo-
sure. Interestingly, the antibody response against SARS-CoV-2 distin-
guished asymptomatic from mild and moderate COVID-19 in
children. Consistent with the observations made in adult COVID-19
patients [25,26], plasma levels of anti-SARS-CoV-2 IgG antibodies
were significantly increased in symptomatic children with COVID-19
(Fig. 5c). As expected, infants under 1 year with COVID-19 had the
lowest levels of anti-SARS-CoV-2 IgG antibodies (Fig. S3c). No differ-
ences were observed according to the sex within the COVID-19 or
MIS-C cohorts. (Fig. S3d).
4. Discussion
Very little is known about the immune response against SARS-
CoV-2 infection in children. Perhaps reflecting that the course of
pediatric disease is usually mild, studies have mainly focused on both
adults and children with MIS-C. A comprehensive review on the
course of infection diseases in children shows that the mild evolution
of pediatric COVID-19 does not represent an exception. Indeed, for a
variety of infections school-age children have the least severe disease
[27]. However, this is not a general rule. Infants and children with
secondary heterologous dengue infections are at most risk for severe
dengue disease [28]. Moreover, severe respiratory syncytial virus
infection is the leading cause of bronchiolitis and hospitalization in
infants causing only minor symptoms in adults [29].
Severe COVID-19 in adults is associated with an overactive inflam-
matory response. It is well established that macrophages and
Fig. 3. Concentration of inflammatory cytokines and NETs in plasma and neutrophil supernatants from children with COVID-19. (a) Plasma levels of IL-1b, IL-6 and IL-8 in healthy
(n = 13) and COVID-19 (n = 40) quantified by ELISA. (b) Plasma levels of cell-free DNA and citrullinated histones H3 in healthy (n = 20 for cell-free DNA and n = 5 for citrullinated his-
tones H3) and COVID-19 (n = 49 for cell-free DNA and n = 19 for citrullinated histones H3) were quantified by fluorometry and ELISA, respectively. (c) Isolated neutrophils (5 £ 106/
mL) from healthy (n = 10) and COVID-19 (n = 40) were cultured for 18 h, and the spontaneous production of IL-1b and IL-8 was analyzed by ELISA. (d) The production of IL-1b and
IL-8 by neutrophils stimulated or not with R848 during 18 h was determined by ELISA in paired samples from healthy (n = 5) and COVID-19 (n = 15). (e) Levels of cell-free DNA in
the supernatant of unstimulated neutrophils (1 £ 106/mL) from healthy (n = 10) and COVID-19 (n = 30) cultured for 4 h at 37 °C were quantified by fluorometry. Median and min to
max of n donors are shown in a-e. P values were determined by Kruskal-Wallis test with Dunn's posttest and Wilcoxon matched-pairs signed rank test: * p < 0.05, **** p < 0.0001.
Controls (white circle), COVID-19 (blue circle). R848, TLR 7/8 agonist resiquimod (For interpretation of the references to color in this figure legend, the reader is referred to the web
version of this article.).
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several lines of evidence suggest that neutrophils also play an impor-
tant role. Increased neutrophil counts and neutrophil-to-lymphocyte
ratio are early indicators of SARS-CoV-2 infection, predicting a worse
outcome [33,34]. High number of neutrophils have been found in the
bronchoalveolar lavage fluid of severe COVID-19 patients while lung
autopsies revealed variable levels of neutrophil infiltration
[21,35,36]. Moreover, increased blood concentrations of a variety of
neutrophil products such as NETs, myeloperoxidase, and calprotectin
have been described in patients with severe COVID-19 [22,37,38].
To our knowledge, no previous study has analyzed the properties
of neutrophils in pediatric COVID-19. Contrasting with the observa-
tions made in adult COVID-19 patients, pediatric COVID-19 is not
associated to lymphopenia, neutrophilia, a high neutrophil/lympho-
cyte ratio or a pro-NETosis neutrophil phenotype. Of note, we found
that the phenotype of neutrophils from children with COVID-19
express a particular signature characterized by a down-regulation in
the expression of adhesion molecules involved in cell migration
together with a high expression of both, the activation markers
CD64, HLA-DR and PECAM-1 and the inhibitory receptors LAIR-1 and
PD-L1. This phenotype is unusual as neutrophil activation is associ-
ated with the up-regulation of adhesion molecules [14] as it was
observed in adult COVID-19 [39]. We hypothesized that the down-
regulation in the expression of adhesion molecules together with a
high expression of inhibitory receptors might prevent neutrophil
infiltration in the pulmonary capillaries thus providing protection
against tissue injury in the children. It is well known that CD11b,
CD66b and L-selectin play a critical role in neutrophil migration andlung infiltration during respiratory infections [40,41]. Moreover,
recent studies have shown that the inhibitory receptor LAIR-1 pre-
vents neutrophil migration and neutrophil-driven airway inflamma-
tion in the course of lung diseases while PD-L1 inhibits the influx of
neutrophils to the airway during tuberculosis infection [42,43].
Although children infected by SARS-CoV-2 are less likely to course
severe illness compared with adults, they are still at risk of develop-
ing a number of complications. In fact, the clinical spectrum of pediat-
ric COVID-19 includes asymptomatic as well as patients with mild,
moderate, severe and critical disease. Our patient cohort includes
174 patients with COVID-19 of which 17% were asymptomatic, and
59% and 25% had a mild and moderate disease, respectively. Our
observations reveal that either the neutrophil expression of CD64 or
the plasma levels of IgG antibodies directed to the spike protein of
SARS-CoV-2 are valuable biomarkers to distinguish asymptomatic
from symptomatic children with COVID-19. These parameters have
previously associated with severe disease in adult COVID-19, and
might be used to stratify patients at admission and identify patients
potentially at risk [44].
The type I IgG receptor (FcgRI or CD64) is the only FcgR that binds
monomeric IgG with high affinity. Many studies have shown that
CD64 is an early and predictive biomarker of neonatal and adult sep-
sis [45,46]. It is normally expressed on monocytes and macrophages
but it is rapidly up-regulated in neutrophils in the course of severe
inflammatory processes [47]. CD64 expression has been recently
reported as a neutrophil activation marker in MIS-C. In the acute
phase of MIS-C the neutrophil expression of CD64 is notably
increased compared with healthy donors but normalized by the
Fig. 4. Neutrophil phenotype, cytokines and NETs levels in children with COVID-19 according to disease severity. (ag) Children with COVID-19 (asymptomatic, mild and moder-
ate) and MIS-C were classified as described in Methods. (ad) Expression of CD11b, CD66b, LAIR-1 and PD-L1 in gated neutrophils was analyzed by flow cytometry in whole blood
samples. (a) CD11b (asymptomatic, n = 13; mild, n = 37; moderate, n = 15 and MIS-C, n = 15); (b) CD66b (asymptomatic, n = 10; mild, n = 17; moderate, n = 8 and MIS-C, n = 19); (c)
LAIR-1 (asymptomatic, n = 7; mild, n = 9; moderate, n = 5 and MIS-C, n = 16); (d) PD-L1 (asymptomatic, n = 3; mild, n = 14; moderate, n = 4 and MIS-C, n = 8). (e) Spontaneous produc-
tion of IL-1-b (left) and IL-8 (right) evaluated in supernatants from unstimulated neutrophils (asymptomatic, n = 10; mild, n = 20; moderate, n = 10 and MIS-C, n = 10). (f) Plasma lev-
els of cell-free DNA (left: asymptomatic, n = 13; mild, n = 24; moderate, n = 12 and MIS-C, n = 17) and citrullinated histones H3 (right: asymptomatic, n = 8; mild, n = 7; moderate,
n = 4 and MIS-C, n = 8). (g) Levels of cell-free DNA in the supernatant of unstimulated neutrophils from asymptomatic, n = 7; mild, n = 16; moderate, n = 7 and MIS-C, n = 11. Dotted
line depicts the median values found in healthy controls. Median and min to max of n donors are shown in a-g. P values were determined by Kruskal-Wallis test with Dunn's post-
test and Mann-Whitney U test: * p< 0.05, ** p< 0.01, *** p < 0.001. Asymptomatic (light green circle), mild (dark green circle), moderate (yellow circle), MIS-C (red circle)(For inter-
pretation of the references to color in this figure legend, the reader is referred to the web version of this article.) .
Fig. 5. CD64 expression and plasma levels of IgG antibodies directed to the spike protein of SARS-CoV-2 in acute and recovered children with COVID-19. (a) Expression of CD64 in
gated neutrophils analyzed by flow cytometry (asymptomatic, n = 6; mild, n = 34; moderate, n = 16, recovered, n = 8 and MIS-C, n = 17). Dotted line depicts the median expression
of CD64 in neutrophils from healthy controls. (b,c). Plasma levels of IgG antibodies directed to SARS-CoV-2 spike protein measured by ELISA. (b) Healthy donors (n = 40), children
with COVID-19 (n = 174) and MIS-C (n = 21). (c) Asymptomatic (n = 29), mild (n = 102), moderate (n = 43) acute COVID-19, recovered COVID-19 (n = 8) and MIS-C (n = 21). Dotted
line indicates the cut-off value in b-c. Median and min to max of n donors are shown in a-c. P values were determined by Kruskal-Wallis test and Mann-Whitney U test: * p < 0.05,
** p < 0.01, **** p < 0.0001. Controls (white circle), COVID-19 (blue circle), asymptomatic (light green circle), mild (dark green circle), moderate (yellow circle), recovered (orange
circle), MIS-C (red circle)(For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.).
8 V. Seery et al. / EBioMedicine 67 (2021) 103357
V. Seery et al. / EBioMedicine 67 (2021) 103357 9resolution phase [44]. In this sense, we wonder if a persistent expres-
sion of CD64 after resolution of acute COVID-19 in children might be
a marker capable to predict a worse outcome and progression to
MIS-C.
As stated before, asymptomatic and symptomatic children with
COVID-19 could be also discriminated by plasma levels of IgG anti-
bodies directed to the spike protein of SARS-CoV-2. This finding is
consistent with a large body of evidence in adults with COVID-19
indicating that disease severity is associated with a greater antibody
response [48,49]. We also observed that MIS-C cohort shows a more
robust antibody response compared with children with COVID-19.
Considering that MIS-C is associated with a prior exposure to SARS-
CoV-2, this observation might just mirror the differential time
elapsed since the onset of infection between both group of patients.
Indeed, Farber and coworkers have recently shown that children
with either acute-COVID-19 (16 days post-symptoms onset) or MIS-C
develop a similar antibody response characterized by a reduced neu-
tralizing activity compared with adult COVID-19, suggesting a less
protective serological response [25].
This study has some limitations. It is important to emphasize
that our cohort did not include any children under severe COVID-
19. Thus, our findings do not differentiate between all clinical
spectrum of COVID-19 and MIS-C. Indeed, biomarkers such as
neutrophil expression of CD64 and inhibitory receptors and
plasma levels of NETs distinguished among asymptomatic, mild
or moderate COVID-19 and MIS-C. However, these markers may
not be able to distinguish severe COVID-19 from MIS-C, two clini-
cal conditions that might share some pathogenic mechanisms.
This issue should be addressed in future cohorts. A second limita-
tion is related to the fact that almost all blood samples from chil-
dren with MIS-C were obtained after starting therapeutic
interventions. Moreover, we were unable to obtain paired sam-
ples from infected children during the acute and convalescent
period. On the other hand, the small volume of blood collected
from each patient limited the performance of studies aimed at
characterizing the functionality of neutrophils. Finally, chest CT
scans were not carried out except for a small group of patients.
Therefore, we could not analyze a possible correlation between
neutrophil phenotype and the degree of lung infiltration.
We still do not understand the reasons why children manage to
face the challenge of SARS-CoV-2 infection so efficiently. As men-
tioned above, the control of infection does not appear to rely on a
more robust antibody response. The function of T cells in pediatric
COVID-19 remains unexplored. Perhaps the basis of the effective con-
trol of SARS-CoV-2 infection in children resides, at least in part, in the
innate immune response. Our present observations suggest that
infection by SARS-CoV-2 in children is associated to the acquisition of
an unconventional phenotype by neutrophils that might prevent
lung infiltration preserving tissue integrity.Declaration of Competing Interest
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